Evidence map›Paper›PMID 26674601›Full record

SynthesisBMC cancer2015

Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis.

Yangyan Jiang, Wenlu Li, Xin He, Hongbo Zhang, Fangzhen Jiang, Zhigang Chen

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. LGR5, HES1 and ATOH1 in Young Rectal Cancer Patients in Egyptian.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yangyan JiangDepartment of UItrasonic diagnosis, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. yangyanjiang11@163.com.
Wenlu LiDepartment of Pharmacology, Zhejiang University School of pharmacy, Hangzhou, China. wenlu256@gmail.com.
Xin HeDepartment of Hematology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 21118135@zju.edu.cn.
Hongbo ZhangDepartment of Neurology, Third people's hospital, Huzhou, China. HongboZhang11@163.com.
Fangzhen JiangDepartment of Plastic surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. fzj198727@163.com.
Zhigang ChenDepartment of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. pridechen@126.com.
Second Affiliated Hospital of Zhejiang University · CNThird People's Hospital of Huzhou · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLgr5 has recently been identified as a reliable biomarker of cancer stem cells (CSCs) in colorectal cancer (CRC); however, its prognostic value is still controversial.

methodsWe searched PubMed, Web of Science, and Wanfang databases with identical strategies to retrieve articles. We evaluated the impact of Lgr5 expression on survival of CRC patients through meta-analysis.

resultsA total of 12 studies comprising 2600 patients revealed that Lgr5 overexpression was negatively associated with overall survival (OS) (HR=1.73, 95% CI: 1.28-2.33; P=0.00) and disease free survival (DFS) (HR=2.89, 95% CI: 1.89-4.44; P=0.000) in CRC patients. Subgroup analysis suggested that Lgr5 overexpression was significantly associated with worse OS in subgroups with IHC as the method of Lgr5 assessment (HR=2.01, 95% CI: 1.39-2.89; P=0.001), patients from Asia (HR=1.81, 95% CI: 1.27-2.58; P=0.000), and NOS scores greater than 6 (HR=2.12, 95% CI: 1.41-3.19; P=0.000). Furthermore, sensitivity analysis showed that the estimated HR ranged from 1.6 to 1.86 upon excluding one study sequentially from each analysis. In addition, Lgr5 overexpression was significantly associated with deep invasion of CRC (OR=0.39, 95% CI: 0.17-0.87; P=0.002), lymphnode metastasis (OR=0.45, 95% CI: 0.26-0.76; P=0.003), distant metastasis (OR=0.37, 95% CI: 0.22-0.62; P=0.000), and AJCC stage (OR=0.35, 95% CI: 0.15-0.78; P=0.01). However, Lgr5 overexpression was not correlated with tumor grade (OR=0.75 95% CI: 0.37-1.54; P=0.433).

conclusionsThis study shows that Lgr5 can be a valuable and reliable prognostic factor of colorectal cancer progression.

Indexed as

AgedBiomarkers, TumorColorectal NeoplasmsDisease-Free SurvivalFemaleHumansMaleMiddle AgedPrognosisReceptors, G-Protein-CoupledBiomarkers, TumorLGR5 protein, humanReceptors, G-Protein-Coupled

Identifiers

PMID26674601
PMCPMC4682230
OpenAlexW2216963744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.